Methylselenocysteine preventing castration‐resistant progression of prostate cancer. Issue 9 (8th March 2015)

• Record Type: Journal Article
• Authors: Liu, Yanbo; Liu, Xichun; Guo, Yaxiong; Liang, Zuowen; Tian, Yong; Lu, Lili; Zhao, Xiaohui; Sun, Ying; Zhao, Xuejian; Zhang, Haitao; Dong, Yan
• Is Part Of: Prostate. Volume 75:Issue 9(2015)
• Page Start: 1001
• Page End: 1008
• Publication Date: 2015-03-08
• Subjects: Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.22987
• Languages: English
• ISSNs: 0270-4137

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pros22987-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Castration‐resistant progression of prostate cancer after androgen deprivation therapy remains a critical challenge in the clinical management of prostate cancer. Resurgent androgen receptor activity is an established driver of castration‐resistant progression, and upregulation of androgen receptor expression has been implicated to contribute to the resurgent androgen receptor activity. We reported previously that methylselenocysteine can decrease the expression and activity of androgen receptor. Here we investigated the ability of methylselenocysteine to inhibit castration‐resistant progression of prostate cancer.</p> </sec> <sec id="pros22987-sec-0002" sec-type="section"> <title>METHODS</title> <p>The regrowth of LNCaP prostate cancer xenografts after castration was monitored. The levels of prostate‐specific antigen in mouse serum were measured by ELISA. Tumor cell proliferation and apoptosis were analyzed via Ki‐67 immunohistochemistry and TUNEL assay, respectively. Intratumoral angiogenesis was assessed by immunohistochemistry staining of vascular endothelial growth factor and CD31.</p> </sec> <sec id="pros22987-sec-0003" sec-type="section"> <title>RESULTS</title> <p>We showed that methylselenocysteine delayed castration‐resistant regrowth of LNCaP xenograft tumors after androgen deprivation. This was accompanied by decreased serum levels of prostate‐specific antigen, inhibition of prostate cancer cell proliferation and tumor angiogenesis, as well as downregulation of androgen receptor and induction of apoptosis in the relapsed tumors.</p> </sec> <sec id="pros22987-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>The present study represents the first to show the preclinical efficacy of methylselenocysteine in delaying castration‐resistant progression of prostate cancer. The findings provide a rationale for evaluating the clinical application of combining methylselenocysteine with androgen deprivation therapy for the treatment of advanced prostate cancer. <italic>Prostate 75:1001–1008, 2015</italic>. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract>